The TEL/ARG oncogene is formed by t(1;12)(q25;p13) reciprocal translocation and is associated with human leukemia. We have previously demonstrated that the expression of TEL/ARG in Ba/F3 cells results in prolonged viability and hyper-responsiveness to IL-3. To determine the molecular mechanisms, a series of mutants of TEL/ARG were generated, and each cDNA was expressed in Ba/F3 or CHO cells. The PNT domain in TEL and K317 in ARG were essential for both signaling and biological effects. The SH3 domain in ARG was required for hyper-responsiveness to IL-3, but not for prolonged viability. The opposite was true for the SH2 domain in ARG. Mutation of Y314 in TEL, a putative GRB2-binding site, led to reduced viability, and loss of hyper-responsiveness to IL-3. All biological functions were profoundly impaired with deletion of the C-terminus in ARG, despite maintaining high levels of its kinase activity. When expressed in CHO cells, wild-type TEL/ARG induced the formation of fillopodia, in a fashion dependent on the C-terminal portion and intact kinase activity. Thus, these results suggest several critical domains within TEL/ARG necessary for function, and indicate that the signaling pathways necessary for viability, growth factor hyper-responsiveness and cytoskeletal reorganization are likely to be separate.
Introduction
ARG is an ABL-related gene, encoding non-receptor protein tyrosine kinase with a similar overall structure (SH3-SH2-kinase domain) to ABL. [1] [2] [3] Recent studies with knockout mice showed that ARG regulates neurulation in the developing mouse embryo in cooperation with ABL, 4 while the biological function of ARG in humans is not well understood yet. The TEL/ARG oncogene has recently been identified in three independent patients with acute leukemia with a reciprocal translocation between chromosomes 1 and 12. [5] [6] [7] All the fusion transcripts from the patients contain the PNT domain of TEL and almost the complete ARG protein. We have previously demonstrated that activated ARG tyrosine kinase of the chimeric molecule and the transforming activity were induced by the expression of TEL/ ARG in the hematopoietic cell lines. 8 Using the sublines, we have also demonstrated that ARG kinase activity is inhibited by the ABL tyrosine kinase inhibitor, STI571. 9 However, the transforming mechanisms of TEL/ARG have not been studied. Although the functional role of each ABL domain has been studied by a number of investigators, little is known about that of ARG. For example, several functional subdomains were identified in the C-terminus of ABL, [10] [11] [12] [13] whereas, only the F-actin and microtubule binding domain has been reported as a functional subdomain in that of ARG so far. 14, 15 The role of TEL in the TEL/ARG oncogene has not been defined either. The TEL gene has been previously identified as a frequent fusion partner of tyrosine kinase oncogenes in patients with leukemia and myeloproliferative disorders. From a previous characterization of transforming TEL-tyrosine kinase fusions (TEL/PDGFRb, TEL/ABL, TEL/JAK2, TEL/TRKC), the PNT domain of TEL is thought to oligomerize and then activate the tyrosine kinase activity of its partner, resulting in a constitutively active tyrosine kinase oncogene that transforms hematopoietic cells in vitro and in vivo. [16] [17] [18] [19] However, TEL may also contribute signaling motifs, such as a putative direct binding site of the GRB2 adapter protein, tyrosine 314 (Y314), since direct binding of GRB2 to BCR at tyrosine 177(Y177) has been reported as one potentially unique contribution of BCR to the transformation of BCR/ABL. 20 Given this background information, we have examined the various signaling domains of TEL and ARG required for signaling and biological effects in the context of the TEL/ARG oncogene.
Materials and methods

Plasmid constructs
The complementary DNA (cDNA) encoding the TEL/ARG (AL) was generated by RT-PCR from HT93A cells with FLAG epitope tags at their 3 0 ends, as described previously. 6 Site-directed mutagenesis was carried out on the pTRE-TEL/ARG plasmid using the ExSite PCR-based site directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's directions. All the constructs were confirmed by DNA sequencing. The complete TEL/ARG cDNA was ligated into either pCMV-HA (Clontech), containing the HA epitope to be tagged at the NH 2 terminus for immunofluorescence staining, or pTRE (Clontech), containing a tet-responsive promoter for further analysis.
Cell lines and cell culture
Ba/F3 is an IL-3-dependent murine hematopoietic pro-B cell line. 21 Ba/F3 cells expressing the reverse Tet transactivator pUHD172-1 (Ton.B.1) were maintained in RPMI 1640, supplemented with 10% FCS and 1 ng/ml of recombinant murine IL-3 (Kirin Inc., Tokyo, Japan). 22 Sublines of Ton.B.1 that expressed the mutant TEL/ARG by induction, were generated by electroporation using a gene pulser (Biorad, Hercules, CA, USA), as described previously. 23 
Antibodies
Antiphosphotyrosine monoclonal antibody (4G10) was provided by Dr Brian Druker (University of Oregon Health Sciences Center, Portland, OR, USA). Rabbit polyclonal anti-ARG antibody, provided by Dr Gary D Kruh (Fox Chase Cancer Center, Philadelphia, PA, USA), was raised against the peptide from the kinase domain of ARG. Anti-Dok, CBL, rasGAP, STAT 5, Raf-1 and HA-tag antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PI3-kinase antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-Shc and paxillin antibodies were purchased from Transduction Laboratories (Lexington, KY, USA). Anti-FLAG M2 antibody was purchased from SIGMA-ALDRICH (St. Louis, MO, USA). Anti-ERK1/2 and phospho-ERK1/2 antibodies were from Cell Signaling Technology (Beverly, MA, USA). BODIPYphalloidin was from Molecular Probes (Eugene, OR, USA).
Immunoblotting and immunoprecipitation
Cells were deprived of growth factors by culturing in RPMI1640 /10% FCS media, and were then stimulated with doxycycline (SIGMA-ALDRICH) as indicated in each experiment. Immunoprecipitation and immunoblotting using a chemiluminescence technique were performed as described previously. 24 
Western blot direct binding assay (Far-Western blot)
Direct in vitro binding of a GST-GRB2 fusion protein (purchased from Santa Cruz Biotechnology) was determined using a previously described method. 24 
Proliferation and viability assays
The number of viable cells was determined using trypan blue, and viable cells were counted using a hemacytometer. Cell concentrations were calculated as the number of cells Â 10 000/ ml. Cell viability was reported as a percentage of the total cells.
Migration assay
Migration assays were performed using Transwell plates (8 mm pore-size polycarbonate membrane, Corning Coster Corp., Cambridge, MA, USA). Both sides of the membrane were coated with human fibronectin (5 mg/ml). The lower chamber contained 600 ml of RPMI1640 containing 0.5% BSA. 0.2 Â 10 6 cells in 100 ml of RPMI1640 containing 0.5% BSA with or without doxycycline were placed into the upper chamber and allowed to migrate into the lower chamber for 5 h at 371C.
Immunofluorescence staining of TEL/ARG in CHO cells CHO cells were used for transient transfection by the lipofection method using Lipofectamine 2000 (GIBCO-BRL), and were cultured in F-12 HAM/10% FCS medium, on fibronectin-coated glass cover slips. The localization of expressed proteins, paxillin and F-actin was evaluated as described previously. 25 Images were taken with an inverted confocal laser scanning microscope (Bio-Rad, Model 1024) and processed using Adobe Photoshop version 7.0. ABL or wild-type TEL/ARG. 23, 24 The ability of mutant TEL/ARG to phosphorylate these proteins was therefore tested (Figure 3 ). The Y314F and DEx.5 mutants had reduced phosphorylation of rasGAP and CBL. DSH3 had no defects in these targets. DSH2 and DC-term were defective on rasGAP, STAT5, Dok, Shc and possibly p85 PI3K, indicating that the SH2 and the C-term domain are important for selecting some substrates.
Direct binding of GRB2 with TEL/ARG
We performed a Western blot binding assay using GRB2-SH2 domain GST fusion protein as probes. As shown in Figure 4a , direct binding with the SH2 domain of GRB2, observed in WT, was eliminated in the Y314F, despite maintaining high levels of kinase activity and overall autophosphorylation. No binding was observed using GST fusion protein alone as a probe. The activation of both Raf and ERK1/2, observed in WT, was also impaired in Y314F (Figure 4b ). Direct binding and the activation were observed in DSH3 and DC-term as well, but not in DPNT nor DEx.5 mutants (data not shown). These results indicate that GRB2 interacts directly with TEL/ARG at phosphorylated Effect of doxycycline-induced TEL/ARG expression on tyrosine phosphorylation of total cellular proteins. Cells were factor deprived for 3 h then incubated with doxycycline 0.5 mg/ml for 6 h. Changes in protein tyrosine phosphorylation were detected by antiphosphotyrosine antibody immunoprecipitation followed by immunoblotting with an antiphosphotyrosine antibody. Molecular masses are shown in kilodaltons.
Figure 3
Tyrosine phosphorylation of signaling proteins in Ton.B TEL/ARG mutants. Cell lysates were immunoprecipitated with antibody as indicated, followed by antiphosphotyrosine immunoblotting with 4G10. The same membrane was stripped and reprobed with the corresponding antibodies. tyrosine 314 in TEL, and initiating a critical signaling pathway that leads to Raf/MAPK pathway activation.
The SH2 domain of ARG is required for viability signaling but not for hyper-responsiveness to IL-3 in Ton.B TEL/ARG cells Each TEL/ARG mutant was tested for the ability to support the proliferation and viabilty of Ton.B cells ( Figure 5 ). There was no biological effect on the cells expressing DPNT and K317R. Compared with the ability of the wild-type TEL/ARG to support viability, DSH3 was equivalent, Y314F and DEx.5 were moderately impaired, and DSH2 and DC-term were profoundly impaired, despite maintaining high levels of kinase activity. The results indicate that the SH2 and C-terminal domain of ARG is required for viability signaling of the TEL/ARG tyrosine kinase.
We next asked if the presence of the mutant TEL/ARG oncogene affected the dose-response of these cells to IL-3. In most of the mutants, there was no significant change in the dose-response curve to IL-3 with and without doxycycline, as observed in Ton.B parental cells, 23 indicating that they lost the ability to induce hyper-responsiveness to IL-3. However, only DSH2 proliferated in response to significantly lower concentrations of IL-3 with doxycycline than without doxycycline, as observed in the WT (Figure 6 ). The maximum rate of proliferation induced by IL-3 was also higher in cells expressing DSH2.
WT and DSH2 TEL/ARG enhance cell migration without affecting b1 integrin expression levels Hematopoietic cells spontaneously migrate on surfaces coated with extracellular matrix proteins when stimulated with hematopoietic growth factors or some oncogenes. The introduction of BCR/ABL into hematopoietic cell lines results in increased cell migration, apparently by affecting the function of b1 integrins. 26, 27 Migration assays were then performed on each of the mutants. As shown in Figure 7 , WT TEL/ARG expression enhanced spontaneous migration. However, none of the mutants tested performed this activity, except for DSH2. The possibility that WT and DSH2 expression augmented b1-integrin surface expression was examined, but FACS analysis with an anti-b1-integrin antibody showed no detectable effect (data not shown). The results of the TEL/ARG mutants on cellular function are summarized in Table 1 .
Actin cytoskeletal abnormalities induced by TEL/ARG are abrogated in DC-term mutant
Since the primary subcellular localization of TEL and ARG is distinct (TEL is located in the nucleus and ARG is located in the cytoplasm), 28, 29 it is important to detect the subcellular localization of the chimeric oncogene to identify its functions in intracellular signaling. In our preliminary study using COS cells, all the TEL/ARG proteins, visualized by tagged EGFP, were detected in the cytoplasm (data not shown).
With regard to the subcellular localization, two F-actinbinding domains have been detected in the ARG C-terminus, 14 thus modulation of the F-actin cytoskeleton is likely one of the cellular functions of TEL/ARG. To examine the spatial distributions of TEL/ARG and F-actin, the actin-cytoskeleton was visualized using alexa phalloidin in CHO cells after transfection with WT, K317R or DC-term TEL/ARG (Figure 8 ). When the phalloidin signal, reflecting F-actin, was accentuated, only the cells expressing the WT exhibited numerous distinct filopodia (A). The cells expressing K317R or DC-term had no filopodium (B, C). Overexpression of c-ARG as a control, did not bring any Figure 5 Proliferation assay in the absence of IL-3. Cells growing in the presence of IL-3 were washed three times with RPMI and resuspended at a density of 0.5 Â 10 6 cells/ml Â 2 ml each in RPMI supplemented with 10% FCS. Cells were then cultured at 371C in the absence or presence of 0.5 mg/ml doxycycline. Total viable cell numbers were evaluated every 24 h. The data presented are the average of five separate experiments.
Molecular dissection of the TEL/ARG oncogene K Okuda et al morphological change to the cells (data not shown). Thus, both tyrosine kinase activity and the C-terminus of ARG are likely required for the development of filopodia. In cells expressing WT, stress fibers were poorly developed and paxillin, a focal adhesion protein, distributed diffusely in the cytoplasm, whereas, cortical F-actin was prominent and there was some accumulation of TEL/ARG (indicated by an arrow:A). In contrast, the cells expressing K317R contained stress fibers and no distinct accumulation of cortical F-actin was noted, as observed in the control. On close examination, a portion of the K317R was found adjacent to the stress fibers (arrow:B), whereas DCterm distributed diffusely in the cytoplasm (C), consistent with the report of F-actin bundling activity in the C-terminus.
Discussion
TEL/ARG fusion was recently identified as a consequence of t(1;12)(q25;p13) in three independent cases, each of which was associated with a different leukemic phenotype. [5] [6] [7] Although 
Figure 6
Dose response of Ton.B. TEL/ARG mutants to IL-3. Cells were washed three times with RPMI and resuspended at a density of 0.5 Â 10 6 cells/ml Â 2 ml each in RPMI supplemented with 10% FCS. Cells were then incubated with the indicated concentration of recombinant IL-3, in the absence or presence of the each oncoprotein by doxycycline induction. Total viable cell numbers in a culture with and without doxycycline were evaluated individually, and the day four cell number is reported in the figure. The data presented are the average of five separate experiments.
Figure 7
Effect on cell migration with TEL/ARG mutants. Cells were used for Transwell migration assays and the number of viable cells in the lower chamber was determined after 5 h by trypan blue exclusion. The migration index was expressed as the ratio of the number of doxycycline-stimulated cells migrating to a number of unstimulated cells migrating over the same time period.
Table 1
Summary of the TEL/ARG effects on biochemical and biological activity Autophosphorylation (kinase activity)
Viability
Hyperresponsiveness to IL-3
The phenotypes of Ton.B cell lines expressing each TEL/ARG oncogene are summarized. The level of activity was compared to untreated counterparts (À) and wild type TEL/ARG induction (++; full activity). The level of autophosphorylation was compared as kinase activity (Figure 1) . The viability and hyper-responsiveness to IL-3 are shown in Figures 5 and 6 , respectively. The mobility was measured by cell migration assay, as shown in Figure 7 .
ARG is highly homologous to ABL, the TEL/ARG translocation is the first instance in which ARG has been implicated in human leukemia, and no other genetic alteration of ARG has been identified in human cancers. On the other hand, ABL fusion proteins, such as BCR/ABL and TEL/ABL, are well-established oncogenes in humans, associated with both chronic and acute leukemia. 30, 31 Thus, neither the molecular functions of ARG nor the transforming mechanisms of TEL/ARG are understood.
Here we have shown that the PNT domain of TEL as well as tyrosine kinase activity of ARG is essential to induce both the biochemical and biological functions of the TEL/ARG oncogene. This result supports the hypothesis that dimerization or oligomerization is the key to the oncogenic activation of ARG. However, it is not proven whether the clustering of the ARG molecule itself is sufficient to activate ARG tyrosine kinase activity to mimic the biological properties of TEL/ARG, as we have previously reported for ABL using a receptor/ABL fusion protein.
32 Y314 in TEL is a putative GRB2 binding site as shown by the immediate C-terminal amino-acid sequence of Y-X-N-X, which is strongly preferred by the GRB2-SH2 domain, 33 and our One documented transforming mechanism of BCR/ABL is Ras activation through interaction with the GRB2/Sos protein complex. The GRB2-SH2 domain binds directly to phosphorylated tyrosine 177 in the BCR portion of BCR/ABL. A tyrosine to phenylalanine mutation (Y177F) at this site was reported to impair Ras activation to decrease the formation of foci in fibroblasts and greatly attenuate the myeloproliferative disease induced by BCR/ABL in mice. 20, 34 A recent investigation demonstrated that phosphorylated tyrosiene 177 recruits the scaffolding adaptor Gab2 via a GRB2/Gab2 complex and this interaction is required for full activation of the PI3K/AKT and Ras/MAPK pathways and myeloid transformation by BCR/ABL. 35 Thus, it is speculated that direct binding of GRB2 to TEL/ARG also contributes to the TEL/ARG-mediated function. We tested this hypothesis using Y314F and DEx.5 mutants. Both mutants showed reduced phosphorylation of rasGAP and CBL. Since CBL constitutively binds GRB2 via the GRB2-SH3 domain, the reduced phosphorylation is thought to be a consequence of limited access to the kinase molecules, possibly to TEL/ARG. Y314F and DEx.5 showed some ability to support viability but did not promote hyper-responsiveness to IL-3, which is characteristic of the WT oncogene. The defect is likely due to a reduction in Ras activity in the mutants, as we observed the impaired activation of the Raf/MAPK pathway in this study. However, there are several other SH2-containing signaling proteins that also prefer the Y-X-N-X motif, the exact role of the phosphoY314 in TEL/ARG will require further study.
The role of the ARG SH2 and SH3 domains in cellular function is contrary and complex. Although the proteins binding to the SH3 or SH2 domain of ARG have not been identified, the high homology between these domains of ARG and ABL suggests that both proteins share common targets. Deletion of the SH3 domain from c-ABL causes oncogenic activation and is associated with an increase in ABL tyrosine kinase activity. 36 It has been suggested that a cellular protein exists that downregulates ABL kinase activity when bound to its SH3 domain, thereby explaining the increased tyrosine kinase activity of SH3 deletion mutants. However, deletion of the SH3 domain in TEL/ ARG did not increase its kinase activity or the tyrosine phosphorylation of cellular proteins compared to the WT. The results suggest that DSH3 induces the activation of the STAT, RAS/MAPK and PI3K/AKT signaling pathways, maintaining full activity in support viability as observed in the WT. Nonetheless, the ability to induce hyper-responsiveness to IL-3, which is likely to be the most important component of the transforming activity of TEL/ARG, was abrogated. On the other hand, the DSH2 mutant was impaired in its ability to promote viability, but induced hyper-responsiveness to IL-3 as much as the WT oncogene. DSH2 was defective in the phosphorylation of rasGAP, STAT5, Doc, Shc, and possibly PI3K, suggesting that an undefined pathway is required for viability, but potentially not for the hyper-responsiveness to IL-3 by TEL/ARG.
Among the mutants studied, the profound effects of deleting the C-terminus domain of TEL/ARG are of interest and suggest an important role for the C-terminal domain in this oncogene. An association with the cytoskeleton has been demonstrated for BCR/ABL, through an evolutionarily conserved G-and F-actinbinding domain at the C-terminus of c-ABL. 37 The presence of BCR/ABL in the cytoskeleton could disrupt the normal structure and signal transduction capacity of various components of the cytoskeleton. 38 However, the contribution of F-actin localization to BCR/ABL-induced oncogenecity remains unclear. 39, 40 We have obtained direct evidence that TEL/ARG is localized at least in part to the actin cytoskeleton through a domain in the Cterminus of ARG, and regulates the cytoskeletal dynamics via its kinase activity. The formation of actin stress fibers and paxillin rich structures was impaired with WT TEL/ARG expression. This alteration was also observed with DC-term, but not K317R, suggesting that part of the cytoskeletal dynamics involved ARG kinase, which was induced without direct access to the actin structures. Furthermore, WT but not K317R or DC-term TEL/ ARG, led to form protrusions of numerous fillopodia from the edges of CHO cells. This striking change apparently required both intact kinase activity and the C-terminus of TEL/ARG. We acknowledge that this system is heterogeneous and more studies of the mechanisms of fillopodium protrusion are necessary. These effects of TEL/ARG on the actin cytoskeleton are potentially related to alterations in integrin-mediated adhesion to extracellular matrix proteins such as fibronectin, as we observed an enhanced effect on cell migration. As the large Cterminal domains of ABL and ARG have less similarity (29% identity), identification of the functional subdomain in the Cterminus is also required to define its role in regulating the biological activity.
An intensive study on TEL/ARG will contribute to the characterization of not only the oncogene but also c-ARG, by creating a signaling pathway from activated ARG. Further refinement of the animal model appears to be required to develop in vivo assays for examining the pathogenic effects of TEL/ARG.
